**2.6 Inclusion of patient information leaflet (PIL) in every product**

Mandatory inclusion of the details of MAH pharmacovigilance person within their organisation (preferably based within every country where their product is marketed) in the PIL accompanying medicines dispensed to patients will assist patients in knowing where to direct their enquiries or reports apart from their National Pharmacovigilance Centres; this can promote ease of reporting by the public/ patients. In other for this initiative to be effective, pharmacovigilance centres along with the policymakers at the MoH will have to develop policies or regulations that will strengthen this position.

Since knowledge is vital in pharmacovigilance, inclusion of PIL in medicines packs that are self-administered by patients will help patients gain knowledge of the medicines they are taking and what ADRs to expect.
